

Technology Advisory Committee C Interests Register

Topic: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]

Publication Date: 03/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Richard Nicholas	Committee member	Direct financial interests	Dr Nicholas has attended paid advisory boards with named comparator companies Novartis and Roche in an unrelated disease area (MS).	N/A	19.05.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
Michael Chambers	Committee member	Direct financial interests	Mr Chambers has co-ordinated a training programme for Roche in Real World Evidence in collaboration with the University of Utrecht, which did not consider any Roche products. He has also participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and provided consulting advice to Sanofi in an unrelated disease area.	N/A	30.01.2023	N/A	It was agreed that his declaration would not prevent Mr Chambers from participating in discussions on this appraisal

Dr Kate Cwynarski	Clinical expert	Direct financial interests	<p>Dr Cwynarski has received</p> <ul style="list-style-type: none"> • consulting/advisory board fees from Roche, Takeda, Celgene, Atara, Gilead, Kite, Janssen and Incyte. • speaker bureau fees from Roche, Takeda, Kite, Gilead and Incyte. • conference/ travel support from Roche, Takeda, Kite, Janssen and BMS. 	N/A	12.10.2021	N/A	It was agreed that her declarations would not prevent Dr Cwynarski from providing expert advice to the committee.
Professor Andrew Davies	Clinical expert	Direct financial interests	<p>Professor Davies has received payment to attend an Incyte hosted clinical advisory board meeting and has reviewed health economic data that in part contributes to this submission, for which he was remunerated. He has received honoraria, advisory and speaker fees from Roche, a comparator company.</p>	N/A	12.10.2021	N/A	It was agreed that his declarations would not prevent Professor Davies from providing expert advice to the committee